BR0215265A - Fludara oral com formulação de alta pureza com liberação rápida do ingrediente ativo - Google Patents
Fludara oral com formulação de alta pureza com liberação rápida do ingrediente ativoInfo
- Publication number
- BR0215265A BR0215265A BR0215265-7A BR0215265A BR0215265A BR 0215265 A BR0215265 A BR 0215265A BR 0215265 A BR0215265 A BR 0215265A BR 0215265 A BR0215265 A BR 0215265A
- Authority
- BR
- Brazil
- Prior art keywords
- fludara
- active ingredient
- high purity
- quick release
- formulation oral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10164510A DE10164510A1 (de) | 2001-12-20 | 2001-12-20 | Orale Fludara reinst Formulierung mit schneller Freisetzung des Wirkstoffes |
PCT/EP2002/013252 WO2003053418A1 (de) | 2001-12-20 | 2002-11-25 | Orale fludara reinst formulierung mit schneller freisetzung des wirkstoffes |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0215265A true BR0215265A (pt) | 2004-12-07 |
Family
ID=7711168
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0215265-7A BR0215265A (pt) | 2001-12-20 | 2002-11-25 | Fludara oral com formulação de alta pureza com liberação rápida do ingrediente ativo |
Country Status (30)
Country | Link |
---|---|
US (1) | US7148207B2 (pt) |
EP (1) | EP1455760B1 (pt) |
JP (2) | JP2005519043A (pt) |
KR (1) | KR100884685B1 (pt) |
CN (1) | CN1306929C (pt) |
AR (1) | AR037965A1 (pt) |
AT (1) | ATE303797T1 (pt) |
AU (1) | AU2002349043B2 (pt) |
BR (1) | BR0215265A (pt) |
CA (1) | CA2471396A1 (pt) |
DE (2) | DE10164510A1 (pt) |
DK (1) | DK1455760T3 (pt) |
EC (1) | ECSP045185A (pt) |
ES (1) | ES2248624T3 (pt) |
HK (1) | HK1077741A1 (pt) |
HR (1) | HRP20040648B1 (pt) |
IL (2) | IL162555A0 (pt) |
JO (1) | JO2363B1 (pt) |
MX (1) | MXPA04006005A (pt) |
NO (1) | NO20043063L (pt) |
NZ (1) | NZ533701A (pt) |
PE (1) | PE20030639A1 (pt) |
RS (1) | RS50398B (pt) |
RU (1) | RU2318496C2 (pt) |
SA (1) | SA03240091B1 (pt) |
TW (1) | TWI255187B (pt) |
UA (1) | UA78741C2 (pt) |
UY (1) | UY27596A1 (pt) |
WO (1) | WO2003053418A1 (pt) |
ZA (1) | ZA200405735B (pt) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010133629A1 (en) * | 2009-05-19 | 2010-11-25 | Grindeks, A Joint Stock Company | Stable pharmaceutical composition of fludarabine phosphate |
US20120010216A1 (en) * | 2010-07-06 | 2012-01-12 | Brown Arthur M | Pharmaceutical compositions containing vanoxerine |
EP2428201A1 (en) | 2010-09-08 | 2012-03-14 | Merck Serono S.A. | Oral administration of nucleoside monophosphates |
CN101947208B (zh) * | 2010-10-09 | 2012-05-23 | 江苏奥赛康药业股份有限公司 | 一种供注射用的磷酸氟达拉滨组合物及其制备方法 |
CN102091046B (zh) * | 2011-02-12 | 2012-07-18 | 海南锦瑞制药股份有限公司 | 一种磷酸氟达拉滨冻干粉针剂及其制备方法 |
CN107922456A (zh) * | 2015-08-28 | 2018-04-17 | 浙江海正药业股份有限公司 | 磷酸氟达拉滨的晶型及其制备方法和用途 |
CN111423458A (zh) * | 2020-04-29 | 2020-07-17 | 东南大学 | 磷酸氟达拉滨杂质h对照品的制备方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3903297A (en) | 1973-11-01 | 1975-09-02 | Upjohn Co | Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs |
US4188378A (en) | 1978-01-04 | 1980-02-12 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine |
US4210745A (en) | 1978-01-04 | 1980-07-01 | The United States Of America As Represented By The Department Of Health, Education And Welfare | Procedure for the preparation of 9-β-D-arabinofuranosyl-2-fluoroadenine |
US4357324A (en) | 1981-02-24 | 1982-11-02 | The United States Of America As Represented By The Department Of Health And Human Services | Prodrug derivatives of 9β-D-arabinofuranosyl-2-fluoroadenine |
DE3323621A1 (de) * | 1982-07-08 | 1984-03-01 | Yamasa Shoyu K.K., Choshi, Chiba | Pharmazeutisches praeparat mit die antitumor-wirkung verstaerkender wirkung, ein solches praeparat enthaltende chemotherapeutische zusammensetzung und verwendung des praeparates zur unterstuetzung der antitumor-behandlung beim menschen und tier |
US5110919A (en) | 1989-12-04 | 1992-05-05 | Ash Stevens, Inc. | Process for the preparation of 2-amino-9-(2,3,5-tri-o-benzyl-beta-d-arabinofuranosyl) adenine and novel intermediates |
FR2701027B1 (fr) | 1993-02-01 | 1997-07-18 | Warner Lambert Co | Procede de synthese ameliore du 9-(beta-d-arabinofuranosyl)adenine 5'-phosphate. |
DE19543052A1 (de) | 1995-11-06 | 1997-05-07 | Schering Ag | Verfahren zur Herstellung und Reinigung von Fludarabin-Phosphat und die Verwendung von sauren Ionenaustauschern im Verfahren |
ATE220543T1 (de) | 1996-04-23 | 2002-08-15 | Janssen Pharmaceutica Nv | Rasch-freisetzende ph-unabhängige feste dosisformen enthaltend cisaprid |
CA2210600A1 (en) * | 1996-07-17 | 1998-01-17 | Takashi Houkan | Inhibitor of tumor metastasis or recurrence |
US6197785B1 (en) * | 1997-09-03 | 2001-03-06 | Guilford Pharmaceuticals Inc. | Alkoxy-substituted compounds, methods, and compositions for inhibiting PARP activity |
IL136283A (en) * | 1997-12-11 | 2006-10-31 | Bayer Schering Pharma Ag | Method for producing fludarabin phosphate |
BR9910481A (pt) | 1998-06-11 | 2001-01-09 | Upjohn Co | Composição farmacêutica para comprimido de liberação não-contìnua |
US6174873B1 (en) * | 1998-11-04 | 2001-01-16 | Supergen, Inc. | Oral administration of adenosine analogs |
AU6646700A (en) | 1999-08-20 | 2001-03-19 | Scripps Research Institute, The | Formation of heterocycles |
WO2001041770A2 (en) | 1999-12-08 | 2001-06-14 | Pharmacia Corporation | Nanoparticulate eplerenone compositions |
US20020131988A1 (en) | 1999-12-16 | 2002-09-19 | Foster Todd P. | Pharmaceutical implant containing immediate-release and sustained-release components and method of administration |
CA2391950A1 (en) * | 1999-12-16 | 2001-06-21 | Todd P. Foster | Implant composition containing melengestrol acetate and trenbolone acetate |
US6399591B1 (en) * | 2000-01-19 | 2002-06-04 | Yung-Shin Pharmaceutical Ind. Co., Ltd. | Chargeable pharmaceutical tablets |
-
2001
- 2001-12-20 DE DE10164510A patent/DE10164510A1/de not_active Ceased
-
2002
- 2002-11-25 MX MXPA04006005A patent/MXPA04006005A/es active IP Right Grant
- 2002-11-25 KR KR1020047009750A patent/KR100884685B1/ko active IP Right Grant
- 2002-11-25 RU RU2004122479/15A patent/RU2318496C2/ru not_active IP Right Cessation
- 2002-11-25 AU AU2002349043A patent/AU2002349043B2/en not_active Ceased
- 2002-11-25 RS YUP-533/04A patent/RS50398B/sr unknown
- 2002-11-25 CA CA002471396A patent/CA2471396A1/en not_active Abandoned
- 2002-11-25 NZ NZ533701A patent/NZ533701A/xx not_active IP Right Cessation
- 2002-11-25 ES ES02781328T patent/ES2248624T3/es not_active Expired - Lifetime
- 2002-11-25 JP JP2003554177A patent/JP2005519043A/ja active Pending
- 2002-11-25 CN CNB028279034A patent/CN1306929C/zh not_active Expired - Fee Related
- 2002-11-25 DE DE50204203T patent/DE50204203D1/de not_active Expired - Lifetime
- 2002-11-25 EP EP02781328A patent/EP1455760B1/de not_active Expired - Lifetime
- 2002-11-25 BR BR0215265-7A patent/BR0215265A/pt not_active Application Discontinuation
- 2002-11-25 DK DK02781328T patent/DK1455760T3/da active
- 2002-11-25 IL IL16255502A patent/IL162555A0/xx active IP Right Grant
- 2002-11-25 AT AT02781328T patent/ATE303797T1/de active
- 2002-11-25 UA UA20040705884A patent/UA78741C2/uk unknown
- 2002-11-25 WO PCT/EP2002/013252 patent/WO2003053418A1/de active IP Right Grant
- 2002-12-10 JO JO2002123A patent/JO2363B1/en active
- 2002-12-19 UY UY27596A patent/UY27596A1/es not_active Application Discontinuation
- 2002-12-20 AR ARP020105054A patent/AR037965A1/es not_active Application Discontinuation
- 2002-12-20 TW TW091136814A patent/TWI255187B/zh not_active IP Right Cessation
- 2002-12-20 US US10/324,141 patent/US7148207B2/en not_active Expired - Fee Related
-
2003
- 2003-01-06 PE PE2003000017A patent/PE20030639A1/es not_active Application Discontinuation
- 2003-04-27 SA SA03240091A patent/SA03240091B1/ar unknown
-
2004
- 2004-06-16 IL IL162555A patent/IL162555A/en not_active IP Right Cessation
- 2004-07-12 EC EC2004005185A patent/ECSP045185A/es unknown
- 2004-07-15 HR HR20040648 patent/HRP20040648B1/xx not_active IP Right Cessation
- 2004-07-19 NO NO20043063A patent/NO20043063L/no not_active Application Discontinuation
- 2004-07-19 ZA ZA2004/05735A patent/ZA200405735B/en unknown
-
2005
- 2005-11-03 HK HK05109796A patent/HK1077741A1/xx not_active IP Right Cessation
- 2005-12-28 JP JP2005379628A patent/JP2006137771A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200901393A1 (ru) | Фармацевтическая композиция, содержащая гестагены и/или эстрогены и 5 метил-(6s)-тетрагидрофолат | |
SE0102438D0 (sv) | New compounds | |
BRPI0415639A (pt) | formas de dosagem de oxicodona de liberação controlada, oral, uma vez por dia | |
MXPA05014082A (es) | Acidos biariloximetilarenocarboxilicos. | |
MXPA06000921A (es) | Derivados de benzamidazoles como inhibidores de mek. | |
BRPI0620229A8 (pt) | formulação | |
BR0311327A (pt) | Composição farmacêutica contendo oxcarbazepina com liberação sustentada de um ingrediente ativo | |
TW200501965A (en) | Highly pure fondaparinux sodium composition,process for preparing said composition and pharmaceutical compositions containing it as active principle | |
TR200401436T4 (tr) | Monotiyogliserol, L-sistem veya tiyoglikolik asitle birlikte pemetrexed içeren farmasötik bileşim | |
BR0215265A (pt) | Fludara oral com formulação de alta pureza com liberação rápida do ingrediente ativo | |
BR0212353A (pt) | Composto, composição farmacêutica, e, uso de um composto | |
MY141020A (en) | Novel pparalpha and ppargamma agonists | |
BG105570A (en) | Pharmaceutical compositions for modified release insulin sensitiser | |
BR0315836A (pt) | Derivados de [6,7-dihidro-5h-imidazol[1,2-alfa]imadazol-3-sulfonila mino]-propionamida, composição farmacêutica, uso do mesmo, bem como processo para sua preparação | |
CA2344686A1 (en) | High purity composition comprising (7.alpha.,17.alpha.)-17-hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn-3-one | |
EA200701686A1 (ru) | Свободное основание лерканидипина | |
AU2003267551A1 (en) | Thieno-pyrrole compounds as antagonists of gonadotropin releasing hormone | |
BR122015015867B8 (pt) | comutador de pé | |
ES2111297T3 (es) | Nuevos esteres de acidos carboxilicos de 2-amino-7-(1,3-dihidroxi-2-propoximetil)purina, su preparacion asi como su empleo. | |
IL159841A0 (en) | Pharmaceutical composition for the treatment of the decline and/or damage of cognitive functions | |
UY26179A1 (es) | Amidas sustituidas del ácido fenilciclohexanocarboxilico y su uso como inhibidores de la incorporación de adenosina. | |
DE50202865D1 (de) | Herstellung reiner stereoisomere von tricyclo-[5.2.1.0(2.6) ]-dec-9-yl-xanthogenat sowie deren verwendung als arzneimittel | |
BRPI0415428A (pt) | formulações terapêuticas | |
AU2002347973A1 (en) | Novel tibolone formulations | |
CR7380A (es) | Formulacion oral de fludara purisimo con liberacion rapida del ingrediente activo |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B25D | Requested change of name of applicant approved |
Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) Free format text: ALTERADO DE: SCHERING AKTIENGESELLSCHAFT |
|
B25A | Requested transfer of rights approved |
Owner name: ALCAFLEU MANAGEMENT GMBH AND CO. KG (DE) Free format text: TRANSFERIDO DE: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT |
|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B15K | Others concerning applications: alteration of classification |
Free format text: PARA.INT.CI.A61K 9/28, A61K 9/20, A61K 31/70, 461P 35/00 Ipc: A61K 9/28 (2011.01), A61K 9/20 (2011.01), A61K 31/ |
|
B25G | Requested change of headquarter approved |
Owner name: ALCAFLEU MANAGEMENT GMBH AND CO. KG (DE) Free format text: ENDERECO ALTERADO CONFORME SOLICITADO NA PETICAO NO 020110064525/RJ DE 20/06/2011. |
|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
B07F | Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] |